Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...

A quadruplet regimen for treating transplant-ineligible, newly diagnosed multiple myeloma (MM), combining the oral drug ixazomib with daratumumab, lower-dose lenalidomide, and dexamethasone (Dara-RId) ...

Results showed the minimal residual disease negativity rate was 52.3% in the D-VRd arm vs 34.8% in the VRd arm. The Food and Drug Administration (FDA) has approved Darzalex Faspro ® (daratumumab and ...

Johnson & Johnson announced the US Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone ...

Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twelfth ...